Are stablecoins a risk to bank deposits?
In a year marked by significant challenges, Haemonetics Corp (NYSE:HAE)’s stock has reached a 52-week low, trading at $59.80. The medical device company, known for its blood management solutions, has seen its shares decline 22% year-to-date, with a current market capitalization of $3 billion. Despite the market’s concerns, InvestingPro analysis suggests the stock is currently undervalued, with a strong financial health score of 3.06 (rated as GREAT). The company maintains healthy fundamentals with a current ratio of 3.97 and has achieved revenue growth of 8.14% over the last twelve months. This latest price level underscores the difficulties Haemonetics has faced in a competitive healthcare market, as it struggles to regain momentum and investor confidence. InvestingPro subscribers have access to 8 additional key insights about Haemonetics, including detailed analysis of its cash flow strength and comprehensive Research Reports that transform complex Wall Street data into actionable intelligence.
In other recent news, Haemonetics Corporation reported third fiscal quarter revenue of $348.5 million, which fell short of the consensus estimate of $353 million. Despite this, the company exceeded expectations in adjusted gross margins and earnings before interest and taxes margins. Haemonetics also announced changes in its executive leadership, appointing Frank Chan as Executive Vice President, Chief Operating Officer, and Roy Galvin as Executive Vice President, Chief Commercial Officer. Meanwhile, several firms have adjusted their price targets for Haemonetics. JMP Securities reduced its target from $125 to $100, maintaining a Market Outperform rating, while BTIG revised its target to $105 from $112, keeping a Buy rating. Needham also adjusted its target to $108 from $112, retaining a Buy rating. These revisions follow Haemonetics’ updated full-year sales guidance and a noted deceleration in organic growth, particularly in plasma sales. Despite these challenges, analysts have expressed optimism about the company’s margin performance and long-term financial targets. Additionally, Bank of America highlighted the potential benefits for Medtech companies, including Haemonetics, from a one-month tariff exemption for USMCA-compliant goods.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.